Singapore Exchange has welcomed the secondary listing of China Medical System Holdings Ltd on its mainboard under the stock code "8A8".

China Medical System Holdings Limited is a specialty pharmaceutical company with strong presence in China for nearly 30 years. Listed on the Hong Kong Stock Exchange since 2010, CMS has built a differentiated portfolio across key therapeutic areas including cardio-cerebrovascular, central nervous system, gastroenterology, dermatology and ophthalmology.

Lam Kong, founder, chairman, chief executive and president of China Medical System Holdings Ltd, said "Our listing in Singapore further enhances our presence in international capital markets."

"By leveraging Singapore's strengths as a hub for global innovation and multinational headquarters, we are advancing our pharmaceutical industry internationalization strategy, accelerating the construction of the full pharmaceutical value chain of R&D, manufacturing and commercialization, and working hand-in-hand with our partners to promote the growth of the pharmaceutical industry in emerging markets and deliver meaningful benefits to patients worldwide," Kong said.

Pol de Win, head of global sales and origination at SGX Group, which owns the Singapore Exchange, said, "We are delighted to welcome China Medical System Holdings Ltd to SGX. As a leading player in the healthcare sector, its listing reflects the rising demand for healthcare innovation and access across Asia. As the company looks to expand in Southeast Asia, its listing on SGX offers a strategic springboard, connecting it to international investors and reinforcing Singapore's role as a hub for capital and growth."